Cutting-edge cardiovascular research uncovers mechanistic insights and potential therapies. Studies identify FAT tissue biology changes as contributors to heart failure with preserved ejection fraction (HFpEF), while novel nomograms advance prognosis prediction for VA-ECMO in septic shock. A landmark clinical trial challenges the efficacy of beta blockers post-myocardial infarction. Additionally, emerging treatments including the cardiac myosin inhibitor aficamten demonstrate improvements in hypertrophic cardiomyopathy management. Collectively, these efforts enhance understanding and therapeutic approaches for cardiovascular diseases.